UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

Company Overview - UNITY Biotechnology, Inc. is focused on developing therapeutics aimed at slowing, halting, or reversing diseases associated with aging [4] - The company is currently concentrating on creating medicines that selectively eliminate or modulate senescent cells, targeting age-related ophthalmologic and neurologic diseases [4] Upcoming Event - UNITY will host a virtual investor event on March 24, 2025, featuring key opinion leader Robert Bhisitkul, MD, PhD, who will discuss the results from the Phase 2b ASPIRE study on UBX1325 [1][2] - The event will include a review of the 24- and 36-week results regarding the safety and efficacy of UBX1325 in patients with diabetic macular edema (DME) [2] Product Information - UBX1325 is an investigational compound being studied for retinal diseases, specifically DME, and is not yet approved for any use [3] - It is a potent small molecule inhibitor of BCL-xL, designed to inhibit the survival of senescent cells, with the aim of improving long-term visual outcomes [3] - The Phase 2 BEHOLD study showed that a single injection of UBX1325 led to a statistically significant improvement in mean best-corrected visual acuity (BCVA) through 48 weeks compared to sham treatment [3]